Literature DB >> 23946388

Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease.

Manuela Polydoro1, Alix de Calignon, Marc Suárez-Calvet, Laura Sanchez, Kevin R Kay, Samantha B Nicholls, Allyson D Roe, Rose Pitstick, George A Carlson, Teresa Gómez-Isla, Tara L Spires-Jones, Bradley T Hyman.   

Abstract

Neurofibrillary tangles (NFTs), a marker of neuronal alterations in Alzheimer's disease (AD) and other tauopathies, are comprised of aggregates of hyperphosphorylated tau protein. We recently studied the formation of NFTs in the entorhinal cortex (EC) and their subsequent propagation through neural circuits in the rTgTauEC mouse model (de Calignon et al., 2012). We now examine the consequences of suppressing transgene expression with doxycycline on the NFT-associated pathological features of neuronal system deafferentation, NFT progression and propagation, and neuronal loss. At 21 months of age we observe that EC axonal lesions are associated with an abnormal sprouting response of acetylcholinesterase (AChE)-positive fibers, a phenotype reminiscent of human AD. At 24 months, NFTs progress, tau inclusions propagate to the dentate gyrus, and neuronal loss is evident. Suppression of the transgene expression from 18 to 24 months led to reversal of AChE sprouting, resolution of Gallyas-positive and Alz50-positive NFTs, and abrogation of progressive neuronal loss. These data suggest that propagation of NFTs, as well as some of the neural system consequences of NFTs, can be reversed in an animal model of NFT-associated toxicity, providing proof in principle that these lesions can be halted, even in established disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23946388      PMCID: PMC3742920          DOI: 10.1523/JNEUROSCI.0881-13.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory.

Authors:  Masahiro Yasuda; Mark R Mayford
Journal:  Neuron       Date:  2006-04-20       Impact factor: 17.173

2.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.

Authors:  A Delacourte; J P David; N Sergeant; L Buée; A Wattez; P Vermersch; F Ghozali; C Fallet-Bianco; F Pasquier; F Lebert; H Petit; C Di Menza
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

Review 3.  Lesion-induced plasticity of central neurons: sprouting of single fibres in the rat hippocampus after unilateral entorhinal cortex lesion.

Authors:  T Deller; M Frotscher
Journal:  Prog Neurobiol       Date:  1997-12       Impact factor: 11.685

4.  Entorhinal cortex of the mouse: cytoarchitectonical organization.

Authors:  T van Groen
Journal:  Hippocampus       Date:  2001       Impact factor: 3.899

5.  The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.

Authors:  Chad A Dickey; Adeela Kamal; Karen Lundgren; Natalia Klosak; Rachel M Bailey; Judith Dunmore; Peter Ash; Sareh Shoraka; Jelena Zlatkovic; Christopher B Eckman; Cam Patterson; Dennis W Dickson; N Stanley Nahman; Michael Hutton; Francis Burrows; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

6.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

7.  Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections.

Authors:  Anyang Sun; Xuan V Nguyen; Guoying Bing
Journal:  J Histochem Cytochem       Date:  2002-04       Impact factor: 2.479

8.  The evolution and pathology of frontotemporal dementia.

Authors:  Andrew Kertesz; Paul McMonagle; Mervin Blair; Wilda Davidson; David G Munoz
Journal:  Brain       Date:  2005-07-20       Impact factor: 13.501

9.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Authors:  Tara L Spires; Jennifer D Orne; Karen SantaCruz; Rose Pitstick; George A Carlson; Karen H Ashe; Bradley T Hyman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits.

Authors:  Julie A Harris; Akihiko Koyama; Sumihiro Maeda; Kaitlyn Ho; Nino Devidze; Dena B Dubal; Gui-Qiu Yu; Eliezer Masliah; Lennart Mucke
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more
  23 in total

1.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 2.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

3.  Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Authors:  Shuko Takeda; Caitlin Commins; Sarah L DeVos; Chloe K Nobuhara; Susanne Wegmann; Allyson D Roe; Isabel Costantino; Zhanyun Fan; Samantha B Nicholls; Alexis E Sherman; Ana T Trisini Lipsanopoulos; Clemens R Scherzer; George A Carlson; Rose Pitstick; Elaine R Peskind; Murray A Raskind; Ge Li; Thomas J Montine; Matthew P Frosch; Bradley T Hyman
Journal:  Ann Neurol       Date:  2016-08-03       Impact factor: 10.422

Review 4.  Role of RAGE in Alzheimer's Disease.

Authors:  Zhiyou Cai; Nannuan Liu; Chuanling Wang; Biyong Qin; Yingjun Zhou; Ming Xiao; Liying Chang; Liang-Jun Yan; Bin Zhao
Journal:  Cell Mol Neurobiol       Date:  2015-07-15       Impact factor: 5.046

5.  Neuroanatomical correlates of atrial fibrillation: a longitudinal MRI study.

Authors:  Adnan I Qureshi; Aveen Saed; Nudrat Tasneem; Malik M Adil
Journal:  J Vasc Interv Neurol       Date:  2014-12

Review 6.  The dendritic hypothesis for Alzheimer's disease pathophysiology.

Authors:  J Nicholas Cochran; Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2013-12-12       Impact factor: 4.077

7.  Array tomography for the detection of non-dilated, injured axons in traumatic brain injury.

Authors:  Rachel E Bennett; David L Brody
Journal:  J Neurosci Methods       Date:  2015-02-14       Impact factor: 2.390

8.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.

Authors:  Sarah L DeVos; Rebecca L Miller; Kathleen M Schoch; Brandon B Holmes; Carey S Kebodeaux; Amy J Wegener; Guo Chen; Tao Shen; Hien Tran; Brandon Nichols; Tom A Zanardi; Holly B Kordasiewicz; Eric E Swayze; C Frank Bennett; Marc I Diamond; Timothy M Miller
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

9.  Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Authors:  Tara L Spires-Jones; Taylor Friedman; Rose Pitstick; Manuela Polydoro; Allyson Roe; George A Carlson; Bradley T Hyman
Journal:  Neurosci Lett       Date:  2014-01-21       Impact factor: 3.046

10.  The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES.

Authors:  Jing L Guo; Arjan Buist; Alberto Soares; Kathleen Callaerts; Sara Calafate; Frederik Stevenaert; Joshua P Daniels; Bryan E Zoll; Alex Crowe; Kurt R Brunden; Diederik Moechars; Virginia M Y Lee
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.